ici 204,219 has been researched along with Bronchial Hyperreactivity in 6 studies
zafirlukast: a leukotriene D4 receptor antagonist
Bronchial Hyperreactivity: Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-four patients with mild-to-moderate asthma were studied using a randomized crossover design with the following three treatment blocks: (1) beclomethasone, 100 microg/d, alone for the first 2 weeks followed by 400 microg/d alone for the next 2 weeks; (2) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of zafirlukast, 20 mg bid; (3) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of theophylline, 200 to 300 mg bid." | 9.10 | Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. ( Dempsey, OJ; Fowler, SJ; Kennedy, G; Lipworth, BJ; Wilson, A, 2002) |
| "In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor." | 9.09 | Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. ( Aziz, I; Dempsey, OJ; Lipworth, BJ; Wilson, AM, 2000) |
| "Twenty-four patients with mild-to-moderate asthma were studied using a randomized crossover design with the following three treatment blocks: (1) beclomethasone, 100 microg/d, alone for the first 2 weeks followed by 400 microg/d alone for the next 2 weeks; (2) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of zafirlukast, 20 mg bid; (3) beclomethasone, 100 microg/d, followed by 400 microg/d, with the addition of theophylline, 200 to 300 mg bid." | 5.10 | Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. ( Dempsey, OJ; Fowler, SJ; Kennedy, G; Lipworth, BJ; Wilson, A, 2002) |
| "In the United Kingdom, about 40% of patients with asthma are homozygous for the glycine-16 beta(2)-adrenoceptor polymorphism, which predisposes them to agonist-induced down-regulation and desensitization of the beta(2)-adrenoceptor." | 5.09 | Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. ( Aziz, I; Dempsey, OJ; Lipworth, BJ; Wilson, AM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Azzam, N | 1 |
| Elsalem, L | 1 |
| Dempsey, OJ | 2 |
| Fowler, SJ | 1 |
| Wilson, A | 1 |
| Kennedy, G | 1 |
| Lipworth, BJ | 2 |
| Cakmak, G | 1 |
| Demir, T | 1 |
| Gemicioglu, B | 1 |
| Aydemir, A | 1 |
| Serdaroglu, E | 1 |
| Donma, O | 1 |
| Männistö, J | 1 |
| Haahtela, T | 1 |
| Westbroek, J | 1 |
| Pasma, HR | 1 |
| Aziz, I | 1 |
| Wilson, AM | 1 |
2 reviews available for ici 204,219 and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Leukotriene D
Topics: Acetates; Airway Remodeling; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Cycl | 2020 |
[New drugs in asthma treatment. Leukotriene receptor blockers and leukotriene synthesis inhibitors].
Topics: Airway Obstruction; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Humans; Indoles; Leuko | 1997 |
4 trials available for ici 204,219 and Bronchial Hyperreactivity